EUCTR2006-002743-89-SE进行中（未招募）不适用
A PHASE III STUDY OF THE ADDITION OF GEMTUZUMAB OZOGAMICIN (MYLOTARG®) DURING INDUCTION THERAPY VERSUS STANDARD INDUCTION WITH DAUNOMYCIN AND CYTOSINE ARABINOSIDE FOLLOWED BY CONSOLIDATION AND SUBSEQUENT RANDOMIZATION TO POST-CONSOLIDATION THERAPY WITH GEMTUZUMAB OZOGAMICIN (MYLOTARG®) OR NO ADDITIONAL THERAPY FOR PATIENTS UNDER AGE 61 WITH PREVIOUSLY UNTREATED DE NOVO ACUTE MYELOID LEUKAEMIA (AML)
Southwest Oncology Group (SWOG)0 个研究点目标入组 684 人开始时间: 2007年2月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 684
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Induction Registration:
- •a. Patients must have a morphologically confirmed diagnosis of acute myeloid leukemia (AML) with FAB classification other than M3, based on bone marrow aspiration and biopsy performed within 14 days prior to registration.
- •Date of bone marrow aspiration/biopsy
- •b. Patients must have reached their 18th birthday but not reached their 61st birthday.
- •c. Patients must have a Zubrod performance status of 0 - 3.
- •d. Patient must have a bilirubin = 2 x Institutional Upper Limit of Normal (IULN). Patients must also have SGOT (AST) = 3 x IULN and SGPT (ALT) = 3 x IULN. Studies must be performed within 14 days prior to registration.
- •e. Patients must have a normal left ventricular function with an ejection fraction = 50% as measured by MUGA scan or two-dimensional echocardiogram within 42 days prior to registration.
- •h. Pretreatment pathology materials must be submitted for morphologic review as described in Section 12.0. Collection of blood and marrow specimens for pathology review must be completed within 14 days prior to registration. Failure to submit pathology materials will render the patient ineligible.
- •i. Patients must be registered on SWOG-9007, the cytogenetics protocol. Collection of pretreatment blood and/or marrow specimens must be completed within 14 days prior to registration. Pretreatment specimens of blood or bone marrow must be submitted to an approved Southwest Oncology Group Cytogenetics Laboratory for cytogenic analysis. Note that this protocol also requires submission of remission and relapse specimens.
- •m. Patients who have known liver disease or known Hepatitis B(HbsAg positive) or Hepatitis C infection are not eligible. If viral status is not known, patients are eligible for study.
- •o. All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •f. Patients with unstable cardiac arrhythmias or unstable angina are not eligible.
- •g. Patients must not have received systemic chemotherapy or more than one dose of intrathecal chemotherapy for acute leukemia. Administration of hydroxyurea to control high cell counts prior to registration is permitted.
- •l. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.
- •k. Patients must not be pregnant or nursing because gemtuzumab ozogamicin may cause fetal harm and because of the potential for serious adverse reactions in nursing infants from the drug. Women/men of reproductive potential must have agreed to use an effective contraceptive method.
研究者
相似试验
进行中（未招募）
1 期
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels as well as the efficacy of Glasdegib as maintenance after transplantation, in adult patients with Acute Myeloid Leukemia (AML), a tumor characterized from an abnormal proliferation of blood cells present in the bone marrow in the form of immature myeloid precursors, ie cells not yet differentiated, called blasts.Favorable-intermediate-risk Acute Myeloid Leukemia (AML)MedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003871-20-ITFONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS414
进行中（未招募）
1 期
Conventional Chemotherapy in combination with or without Gemtuzumab Ozogamicin (Mylotarg) in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia (a serious malignant blood disorder which is fatal if not treated)Acute myeloid leukaemiaEUCTR2016-001533-28-Outside-EU/EEAChildren's Oncology Group1,070
进行中（未招募）
1 期
A study to see if Gemtuzumab Ozogamicin is a useful treatment for patients with Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) or cancer that has come back (relapsed) or has not responded (refractory) to treatment.Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) and relapsed/refractory solid tumoursMedDRA version: 21.1Level: PTClassification code 10071583Term: Haemophagocytic lymphohistiocytosisSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 21.1Level: LLTClassification code 10053867Term: Macrophage activation syndromeSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2020-002428-36-GBniversity of Birmingham20
进行中（未招募）
2 期
A study to see if a drug called gemtuzumab ozogamicin is a useful treatment for patients with immune disorders called haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS), or for patients with cancerHaemophagocytic lymphohistiocytosis, macrophage activation syndrome, relapsed/refractory solid tumoursMalignant neoplasms of ill-defined, secondary and unspecified sitesCancerISRCTN89158144niversity of Birmingham20
进行中（未招募）
1 期
Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM] - GO-A-HAMEUCTR2004-003739-30-ATniversitätsklinikum Ulm / University Clinical Center Ulm84